Investor Relations
Our Vision

We look for answers in unexpected places & vigorously test our hypotheses to deliver ground-breaking advances to patients.

Careful Planning for Success

Inmedix specializes in understanding how stress impacts disease

For our first patented project, fibromyalgia (FM), we conducted three clinical studies, including randomized, placebo-controlled trials negotiated with the FDA, prior to monetizing the value of our research with an international patent portfolio sale in 2007. 

The current Inmedix project is to bring cloud-based heart rate variability (HRV) from professional sports, through appropriate, regulated pathways (FDA), for validated applications to improves healthcare.

Inmedix is a privately held corporation (DE) that seeks like-minded individuals and institutions to support our mission of significantly enhancing established therapies for autoimmune disease through assessment, optimization and maintenance of optimal autonomic nervous system (ANS).  Please contact our Corporate Development Team for more information about Inmedix.


This website contains certain forward-looking statements, including without limitation statements regarding Inmedix’s plans for preclinical studies and product capabilities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Inmedix’s business which could significantly affect expected results, including without limitation, progress of development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures.  All forward-looking statements are qualified in their entirety by this cautionary statement, and Inmedix undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release. This is not an offer to sell or an offer to purchase securities.